Sulfameth

Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim

Retrieved on: 
Tuesday, August 4, 2020
Supply chain management, Professional services, Retail, Health, Hospitals, Consulting, Pharmaceutical, Chemical compounds, Drugs, RTT, Aromatic amines, Aromatic compounds, Sulfameth, Trimethoprim, Sulfonamide, Urinary tract infection

(NASDAQ: PINC), through its ProvideGx program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19.

Key Points: 
  • (NASDAQ: PINC), through its ProvideGx program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19.
  • Somerset is a new market entrant for this drug, working to creating a viable, competitive alternative and second source of supply.
  • At the same time, this deal provides a long-term contract to Somerset, creating predictable demand for years into the future.
  • Together with privately owned, U.S.-based Somerset Therapeutics, established in 2015, Somerset develops, manufactures and markets generic injectable and ophthalmic drugs.

ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL

Retrieved on: 
Wednesday, February 12, 2020
RTT, Chemical compounds, Medical specialties, Medicine, Aromatic amines, Antibiotics, Antimetabolites, Pyrimidines, Trimethoprim, Sulfamethoxazole, Shigellosis, Sulfameth

BAUDETTE, Minn., Feb. 12, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL.The current annual market for this product is approximately $29 million, according to IQVIA.This launch represents ANI's third generic product introduction in 2020.

Key Points: 
  • BAUDETTE, Minn., Feb. 12, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL.The current annual market for this product is approximately $29 million, according to IQVIA.This launch represents ANI's third generic product introduction in 2020.
  • Arthur S. Przybyl, ANI's President and CEO commented, "This is the twelfth product that ANI has successfully launched from our library of discontinued NDAs and ANDAs.
  • Sulfamethoxazole and Trimethoprim Oral Suspension is indicated in the treatment and prevention of various infections proven or strongly suspected to be caused by susceptible bacteria which include urinary tract infections, acute otitis media, bronchitis, shigellosis, Pneumocystis jirovecipneumonia, and traveler's diarrhea.
  • ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID

Retrieved on: 
Wednesday, April 3, 2019
Chemical compounds, Aromatic amines, Aromatic compounds, Organic compounds, RTT, Communication, Forward-looking statement, Sulfameth, Risk, Trimethoprim

Oral ibrexafungerp was evaluated at two dose levels (15mg/kg or 30mg/kg, twice daily), compared to trimethoprim/sulfamethoxazole 50/250mg/kg three times weekly, the current standard of care, and vehicle control.

Key Points: 
  • Oral ibrexafungerp was evaluated at two dose levels (15mg/kg or 30mg/kg, twice daily), compared to trimethoprim/sulfamethoxazole 50/250mg/kg three times weekly, the current standard of care, and vehicle control.
  • The ECCMID 2019 posters will be available on the SCYNEXIS website following the event and on the ECCMID 2019 website.
  • Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
  • These risks and uncertainties include, but are not limited to, risks inherent inSCYNEXIS'sability to successfully develop and obtainFDAapproval for ibrexafungerp.

SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019

Retrieved on: 
Thursday, February 28, 2019
Chemical compounds, Drugs, RTT, Aromatic amines, Aromatic compounds, HIV/AIDS, Pneumocystis pneumonia, Pneumonia, Infectious diseases, Trimethoprim/sulfamethoxazole, Trimethoprim, Sulfameth

The presentation will take place on March 18th at 4PM GMT at Superbugs and Superdrugs 2019, March 18-20, 2019, in London.

Key Points: 
  • The presentation will take place on March 18th at 4PM GMT at Superbugs and Superdrugs 2019, March 18-20, 2019, in London.
  • The oral presentation, entitled: "Activity of oral ibrexafungerp in murine models of Pneumocystis pneumonia," will be delivered by Stephen A. Barat, Ph.D., Vice President, Pre-clinical Research and Early Clinical Development at SCYNEXIS.
  • The presentation highlights the results from multiple animal studies that evaluated oral ibrexafungerp versus both trimethoprim/sulfamethoxazole, which is the current standard of care for PCP, and vehicle control.
  • Oral ibrexafungerp demonstrated strong activity againstPCP in this model, as determined by a reduction in organism burden and improved survival.